News Sentiment

CYTK sentiment intelligence

Cytokinetics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 84.87 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-1.9% over one week, +21.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -1.9% Price digesting
Trend fit Trend active 21.0% over four weeks
Fair value 58.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 37
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 11
simplywall.st 7
Simply Wall Street 4
Investing.com 3
Investing.com Canada 3
TradingView 3
DirectorsTalk Interviews 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 17
Regulatory and legal 7
Analyst action 4
Deals and strategy 3
Balance sheet 1
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 64
Investing.com Canada Direct company coverage

Form 4 Cytokinetics Inc For: 2 July By Investing.com

Investing.com reports on a Form 4 filing for Cytokinetics Inc. on July 2nd. The article reiterates this information and provides general market data, including various stock market indices, commodity prices, bond yields, and trending stocks. It also features popular financial new

Tone
Neutral 50/100
Event
Macro sensitivity
Published
02 Jul 2026 21:39
Source
Investing.com Canada
Stock Titan Direct company coverage

Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80

Andrew Callos, EVP of Cytokinetics (NASDAQ: CYTK), exercised options to acquire 15,000 shares of common stock at $23.26 per share and subsequently sold all 15,000 shares in an open-market transaction at an average price of $85.80 per share on July 1, 2026. Following these transac

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

Cytokinetics (NASDAQ: CYTK) CEO trims stake with 7,500-share sale

Cytokinetics President & CEO Robert I. Blum sold 7,500 shares of CYTK common stock at $84.92 per share in an open-market transaction on July 1, 2026. Following the sale, Blum directly holds 377,830 shares, with an additional 2,083 shares each held indirectly by two irrevocable tr

Tone
Negative 31/100
Event
Deals and strategy
Published
02 Jul 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

CYTK insider Robert Blum notifies planned sale of 44,990 shares (CYTK)

Robert Blum, an insider at Cytokinetics Inc. (CYTK), has filed a Form 144 to report planned sales of company stock, including 44,990 shares from stock option exercise and 7,510 shares from Restricted Stock Units. The filing also details several completed 10b5-1 sales of 7,500 sha

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:09
Source
Stock Titan
Simply Wall Street Direct company coverage

Cytokinetics (CYTK) Is Up 6.5% After Myqorzo’s Early Commercial Uptake Signals Growing Clinical Interest – Has The Bull Case Changed?

Cytokinetics is seeing a 6.5% stock increase driven by the early commercial success of its heart drug, Myqorzo, which has received regulatory approvals in the US, Europe, and China. The early adoption by physicians and patients is validating the drug's potential, shifting the com

Tone
Positive 70/100
Event
Regulatory and legal
Published
30 Jun 2026 22:23
Source
Simply Wall Street
Investing.com Direct company coverage

Cytokinetics Inc stock hits 52-week high at $88.00

Cytokinetics Inc (CYTK) stock reached a new 52-week high of $88.00, marking a significant 159.39% increase over the past year due to substantial revenue growth and positive analyst sentiment. The company's heart drug, Myqorzo, has seen a successful commercial launch in Germany an

Tone
Positive 74/100
Event
Earnings
Published
30 Jun 2026 13:40
Source
Investing.com